Elvitegravir: A new HIV integrase inhibitor

Antiviral Chemistry and Chemotherapy

Volumn 20, Issue 2, 2009, Pages 79-85

  Shimura, Kazuya ^a   Kodama, Eiichi N ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; INTEGRASE; RALTEGRAVIR; RITONAVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LENTIVIRINAE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS;

DRUG RESISTANCE, NEOPLASM; HIV INTEGRASE INHIBITORS; HUMANS; QUINOLONES; RETROVIRIDAE;

EID: 70449411340     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1397     Document Type: Article

References (39)

1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Machouf N, Thomas R, Nguyen VK, et al. Effects of drug resistance on viral load in patients failing antiretroviral therapy. J Med Virol 2006; 78:608-613.
3. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008; 10:67-84.
4. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991; 67:1211-1221.
5. LaFemina RL, Schneider CL, Robbins HL, et al. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 1992; 66:7414-7419.
6. Sayana S, Khanlou H. Raltegravir: the first in a new class of integrase inhibitors for the treatment of HIV. Expert Rev Anti Infect Ther 2008; 6:419-426.
7. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
8. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
9. Dejesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43:1-5.
10. Zolopa A, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 143LB.
11. Sato M, Motomura T, Aramaki H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006; 49:1506-1508.
12. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008; 51: 5843-5855.
13. Kobayashi M, Nakahara K, Seki T, et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 2008; 80:213-222.
14. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82:764-774.
15. Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62:914-920.
16. Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65.
17. Tantillo C, Ding J, Jacobo-Molina A, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994; 243:369-387.
18. Turlure F, Devroe E, Silver PA, Engelman A. Human cell proteins and human immunodeficiency virus DNA integration. Front Biosci 2004; 9:3187-3208.
19. Marinello J, Marchand C, Mott BT, et al. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008; 47:9345-9354.
20. Savarino A. In-silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007; 4:21.
21. Nair V, Chi G, Ptak R, Neamati N. HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent. J Med Chem 2006; 49:445-447.
22. Nair V, Ma X, White C, et al. INH-I001, a HIV integrase inhibitor with potent in vitro anti-HIV activity: microsome and cytosol stability studies, cytochrome P450 data and pharmaco kinetics. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 734.
23. ClinicalTrials.gov. Phase 3 study of the safety and efficacy of ritonavir-boosted elvitegravir (EVG/r) versus raltegravir (RAL). (Updated 20 April 2009. Accessed 28 August 2009.) Available from http://www.clinicaltrials.gov/ct2/show/NCT00707733
24. Gilead. Gilead outlines R & D priorities for 2009 - advancing a new single tablet regimen for HIV. (Accessed 9 February 2009.) Available from http://www.gilead.com/pr_1248979
25. Mathias A, Lee M, Callebaut C, et al. GS-9350: a pharmacoenhancer without anti-HIV activity. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 40.
26. Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007; 45:274-279.
27. Garvey EP, Johns BA, Gartland MJ, et al. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 2008; 52:901-908.
28. Goethals O, Clayton R, van Ginderen M, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82:10366-10374.
29. McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Antivir Ther 2007; 12 Suppl 1:S11.
30. Charpentier C, Karmochkine M, Laureillard D, et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008; 9:765-770.
31. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 1998; 279:1984-1991.
32. Julg B, Goebel FD. HIV genetic diversity: any implications for drug resistance? Infection 2005; 33:299-301.
33. Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003; 5:25-35.
34. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 12:563-570.
35. Xu L, Anderson J, Ferns B, et al. Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. AIDS Res Hum Retroviruses 2008; 24:1003-1007.
36. Hazuda DJ, Young SD, Guare JP, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004; 305:528-532.
37. Savarino A, Pistello M, D'Ostilio D, et al. Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology 2007; 4:79.
38. Pluymers W, Pais G, Van Maele B, et al. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives. Antimicrob Agents Chemother 2002; 46:3292-3297.
39. Hazuda DJ, Anthony NJ, Gomez RP, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A 2004; 101:11233-11238.